Molecule of the month: catumaxomab.
D018033:Antibodies, Bispecific / Q000494:pharmacology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000187:drug effects / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy* / Q000503:physiopathology; D015815:Cell Adhesion Molecules / Q000187:drug effects / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000071858:Epithelial Cell Adhesion Molecule; D006801:Humans
D018033:Antibodies, Bispecific; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D015815:Cell Adhesion Molecules; D000071858:Epithelial Cell Adhesion Molecule; C522419:catumaxomab